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A case-only study to identify genetic modifiers of
breast cancer risk for BRCA1/BRCA2 mutation
carriers
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial
factors. About 50 common variants have been shown to modify BC risk for mutation carriers.
All but three, were identified in general population studies. Other mutation carrier-specific
susceptibility variants may exist but studies of mutation carriers have so far been under-
powered. We conduct a novel case-only genome-wide association study comparing genotype
frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or
BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and
3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the
general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes
previously implicated in BC biology, are predicted as potential targets. These findings will
contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation
carriers.
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Breast cancer (BC) is the most common cancer in womenworldwide1 and BC family history is one of the mostimportant risk factors for the disease. Women with a his-
tory of BC in a first-degree relative are about two times more
likely to develop BC than women without a family history2.
Around 15–20% of the familial risk of BC can be explained by
rare mutations in the BRCA1 or BRCA2 genes3. A recent pro-
spective cohort study estimated the cumulative risk of BC by 80
years to be 72% for BRCA1 mutation carriers and 69% for BRCA2
mutation carriers4. This study also demonstrated that BC risk for
mutation carriers varies by family history of BC in first and
second degree relatives, suggesting the existence of other genetic
factors that modify BC risks4.
A total of 179 common BC susceptibility single nucleotide
polymorphisms (SNPs) or small insertions or deletions (INDELs)
have been identified through genome-wide association studies
(GWAS) in the general population1,5–35. Although risk alleles at
individual SNPs (hereafter used as a generic term to refer to
common variants, which also includes the small INDELs) are
associated with modest increases in BC risk, it has been shown
that they combine multiplicatively on risk, resulting in substantial
levels of BC risk stratification in the population36–38. Similarly,
more than 50 of the common genetic BC susceptibility variants
have also been shown to be associated with BC for BRCA1 and
BRCA2 mutation carriers5,6,15,18,20,39–48 and their joint effects,
summarised as polygenic risk scores (PRS), result in large dif-
ferences in the absolute risks of developing BC for mutation
carriers at the extremes of the PRS distribution49. BC GWAS for
BRCA1 and BRCA2 mutation carriers have been carried out
through the Consortium of Investigators of Modifiers of BRCA1/2
(CIMBA)50. However, despite the large number of BRCA1 and
BRCA2 mutation carriers included, the power to detect genetic
modifiers of risk remains limited in comparison to that available
in the general population7. To date, no variants specifically
associated with BC risk for BRCA1 and BRCA2 carriers have been
identified.
Here, we apply a novel strategy using a case-only GWAS
design51,52, in which SNP genotype frequencies in 7,257 BRCA1
and 5,097 BRCA2 mutation carrier BC cases are compared to
those in 60,212 BC cases from the Breast Cancer Association
Consortium (BCAC), unselected for mutation status. We aim (1)
to identify novel SNPs that modify BC risk for BRCA1 or BRCA2
mutation carriers but are not associated with risk in the general
population and (2) for the known 179 BC susceptibility SNPs,
assess whether there is evidence of an interaction between the
SNPs and BRCA1 or BRCA2 mutations and therefore evaluate
whether the SNP effect size estimates applicable to mutation
carriers are different.
We identify robust novel associations for 2 variants with BC for
BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci,
which are not associated with risk in the general population. They
include rs60882887 in 11p11.2 where MADD, SP11 and EIF1,
genes previously implicated in BC biology, are predicted as
potential targets. These findings will contribute towards custo-
mising BC PRS for BRCA1 and BRCA2 mutation carriers.
Results
Sample characteristics. A total of 60,212 BCAC cases and 7,257
BRCA1 mutation carrier cases were available for the BRCA1 case-
only analyses and 57,725 BCAC cases and 5,097 BRCA2 mutation
carrier cases were available for the BRCA2 case-only analyses
(Fig. 1). A total of 45,881 BCAC controls and 5,750 unaffected
BRCA1 mutation carriers were available for the BRCA1 control-
only analyses and 43,549 BCAC controls and 4,456 unaffected
BRCA2 mutation carriers for the BRCA2 control-only analyses
(see Fig. 2). Only women of European ancestry were included
with 60.9% samples from European countries, 31.1% from the
USA, 6.1% from Australia and 1.7% from Israel (Supplementary
Tables 1–4). The mean age at BC diagnosis for mutation carrier
cases in CIMBA was 42.5 years (40.9 for BRCA1 mutation car-
riers; 44.1 for BRCA2 mutation carriers) and 58.4 years for cases
in BCAC.
The analytical process for assessing interactions with known
BC susceptibility SNP is summarised in Fig. 3 and for the
detection of novel modifiers in Fig. 4.
Independence of SNP frequency with mutation carrier status.
Under a case-only study design, it is important to establish
independence between the SNPs and BRCA1 or BRCA2 mutation
carrier status53. This was assessed a genome-wide level using a
control-only analysis which included controls from BCAC and
unaffected mutation carriers from CIMBA with SNP data
imputed based on the 1,000 genomes project. Genotypes had been
a b.
Fig. 1 Case-only sample selection. Sample selection for a BRCA1 and b BRCA2 case-only analysis. *Four studies were excluded because they were included
in clinical trials based on breast tumour characteristics as HER-2 receptor status (see Supplementary Table 2).
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imputed separately by each consortium7,50. In the analysis of
BRCA1mutation carriers, 2,164 SNPs were excluded because they
were located in or within 500 kb of BRCA1. 2,070 SNPs were
excluded from further analyses because they showed associations
at p < 10−8 with BRCA1 mutation carrier status in the control-
only analysis (2,012 SNPs located on chromosome 17 and 58 on
other chromosomes). In the analysis of BRCA2 mutation carriers,
2,947 SNPs were excluded because they were located in or within
500 kb of BRCA2. A further 626 SNPs were excluded from further
analyses because they were found to be associated with BRCA2
mutation carrier status in the control-only analysis (566 SNPs on
chromosome 13, and 60 on other chromosomes). A total of
9,068,301 SNPs remained for the BRCA1case-only association
analysis and 9,043,830 SNPs for the BRCA2case-only analysis.
Interactions with known BC susceptibility SNPs. Based on
published data, 179 SNPs were considered as established BC
susceptibility SNPs (Fig. 3); 158 SNPs were associated with overall
BC risk35 and 21 additional SNPs were found to be associated
through studies in ER-negative breast cancer48 (see Supplemen-
tary Table 11 in Milne et al.48). One of the 158 SNPs, rs11571833
located within BRCA2 was excluded from the BRCA2 analysis.
The detailed results are shown in Supplementary Data 1–3.
For BRCA1 mutation carriers, previous studies have demon-
strated heterogeneity in the associations of the SNPs with ER-
positive and ER-negative breast cancer35. Since BRCA1 mutation
carriers develop primarily ER-negative BC, to comprehensively
assess the evidence of interaction with BRCA1mutation status, we
followed a two-step process; we first assessed the associations
using all BC cases from BCAC and then we restricted the
comparison to BCAC ER-negative BC cases. Of the 158 SNPs35,
59 were associated with BRCA1 mutation carrier status when
compared to all BC cases (P < 0.05, Supplementary Data 1).
However, after adjusting for multiple testing, only four of these
a. b.
Fig. 2 Control-only sample selection. Sample selection for a BRCA1 and b BRCA2 control-only analysis.
Fig. 3 Analytical process for known BC susceptibility SNPs. Strategy followed for analysing the associations for the 179 known BC susceptibility SNPs.
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SNPs were associated (P < 2.7 × 10−4) and also showed evidence
of association (P < 0.05) when compared with ER-negative BC
cases (Table 1). Two additional SNPs on chromosome 1 and 6
(chr1_10566215_A_G and rs17529111) were associated at P <
2.7 × 10−4 with BRCA1 mutation status only when compared
with ER-negative BCAC cases. The OR estimates for association
with BRCA1 mutation status for these six SNPs were similar
under both case-only analyses (all BC and ER-negative BC cases
analyses) and varied from 0.85 to 1.07, suggesting that the
magnitude of their associations with BC risk for BRCA1 mutation
carriers differs from that observed in the general population. For
the other 152 SNPs, there was no evidence of association with
BRCA1 mutation status when compared against the ER-negative
BC cases from BCAC (Supplementary Data 1), suggesting that the
OR estimated using case-control data from BCAC are also
applicable to BRCA1 mutation carriers.
Among the 21 ER-negative SNPs reported in Milne et al.48,
only one (rs66823261) demonstrated significant evidence of
association in the ER-negative case-only analysis (OR= 0.88, p <
2.7 × 10−4) (Table 1 and Supplementary Data 2). For the 20 other
showing no association, the ORs estimated in Milne et al.48 would
be applicable to BRCA1 mutation carriers.
To estimate the association of the seven significant SNPs with
BC for BRCA1 mutation carriers (ORcomputed), the OR estimated
using case-control data from BCAC (ORBCAC) was multiplied by
the OR estimated using the case-only analysis (OR). For three
SNPs, rs17426269, chr10_80841148_C_T and rs17529111, the
magnitude of the association with BC for BRCA1 mutation car-
riers was greater than that in the general population (ORBCAC)
and for two of these three, the ORcomputed was in the opposite
direction than the ORBCAC (Table 1). For the four other SNPs
(rs13281615, chr16_52599188_C_T, chr1_10566215_A_G and
rs66823261), the estimated interaction OR resulted in the OR for
associations with BRCA1 BC risk being closer to 1 (Table 1).
Among the remaining 172 SNPs (152+ 20) that showed
no associations with BRCA1 mutation status, the estimated
ORcomputed was smaller (i.e., closer to 1) than those estimated
in the general population (ORBCAC) for 146 SNPs (85%,
Fig. 4 Analytical process for identifying novel modifiers. Strategy followed for identifying potentially novel SNP modifier.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20496-3
4 NATURE COMMUNICATIONS |         (2021) 12:1078 | https://doi.org/10.1038/s41467-020-20496-3 | www.nature.com/naturecommunications
Supplementary Data 1 and 2). Based on the analysis of
ER− tumours, the proportion of SNPs for which the ORcomputed
was closer to 1 than the ORBCAC estimates was 59% (Supplemen-
tary Data 1 and 2).
For BRCA2 mutation carriers, among the 157 SNPs known to
be associated with BC risk in the general population, 43 were
associated with BRCA2 mutation carrier status at P < 0.05 in the
case-only analysis that included all BCAC BC cases (Supplemen-
tary Data 3). However, only three SNPs (rs62355902, rs10759243
and chr22_40876234_C_T) showed associations after adjusting
for multiple testing (P < 2.7 × 10−4) with OR estimates in the
range of 0.88 to 0.89 (Table 2).
For these three SNPs, the observed interaction resulted in the
magnitude of association with BC risk for BRCA2 mutation
carriers (ORcomputed) being closer to 1 (Table 2).
Of the 154 SNPs that showed no significant associations with
BRCA2mutation status, 79% had ORs of BC for BRCA2mutation
carriers (ORcomputed) that were closer to 1 when compared to the
ORs estimated using data in the general population (ORBCAC)
(Supplementary Data 3).
Novel SNP modifiers. To identify novel SNPs that modify BC
risks for BRCA1 and BRCA2 mutation carriers, we used a case-
only design to investigate the associations of SNPs that
had not been previously shown to be associated with BC in the
general population (Fig. 4).
For BRCA1 mutation carriers, a total of 924 SNPs showed
associations at P < 10−8 in all BC case-only analysis. To ensure
that none of these associations are driven by differences in the
distribution of ER-positive and ER-negative tumours in BCAC
cases, an intermediate step was applied, in which we re-analysed
the associations after restricting the BCAC data to only
ER-negative cases. 220 of these SNPs remained significant at
P < 10−7 located in 11 distinct genomic regions. SNPs were
considered to belong to the same region if they were located
within 500 kb of each other.
To ensure that none of these associations was driven by
differences in the genotype imputation in the BCAC and CIMBA
data (which had been carried out separately), all the SNPs in
these 11 distinct genomic regions were re-imputed in the BCAC
and CIMBA samples jointly and the associations for all SNPs in
the regions were re-assessed in the control-only and case-only
analyses. After the exclusion of 614 SNPs (613 on chromosome
17) that showed associations in the control-only analysis, 71
SNPs in two regions remained significant at P < 10–8 (Supple-
mentary Data 4) in the case-only analyses including all BCAC
cases. None of these SNPs had been previously reported in
GWAS in the general population (p-values of association ranged
from 0.51 to 5.9 × 10−5 with effect sizes in the range 0.96–1.04 in
BCAC case-control analyses)35,48. A forward step-wise regression
analysis within each of these two regions (restricted to the SNPs
exhibiting associations at p < 10−8) starting with the most
significant SNP and adding sequentially the other SNPs,
identified a set of four conditionally independent SNPs (top
SNPs) (Table 3): all SNPs were imputed, with r2 > 0.5, and had
minor allele frequency (MAF) > 10%. Three of the top SNPs are
located in 17q21.2. rs58117746 is an insertion of 16 bp within an
exon of KRTAP4-5 leading to a frameshift of the amino acid
sequence. rs5820435 and rs11079012 are both intronic and
located in LEPREL4 (also named P3H4) and JUP, respectively,
while rs80221606 is intronic and located in 11p11.2, within
CELF1. The OR estimates of these four top SNPs ranged from
0.78 to 1.22. All showed evidence of heterogeneity in the OR by
country (P < 0.05) (Table 3); however, in a leave-one-out analysis,
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associations remained similar (Supplementary Fig. 1 and 2)
suggesting that no individual country had a big impact on the
observed associations.
For BRCA2 mutation carriers, the case-only analysis identified
273 SNPs, located across 22 regions, with evidence of association
at P < 10−8. After the joint re-imputation of the SNPs in these 22
regions, only 102 SNPs located in four regions (2p14, 13q13.1,
and 13q13.2) remained associated at P < 10–8 (Supplementary
Data 5). The step-wise regression analysis suggested that
associations in each of the four regions were driven by a single
variant (top SNPs) (Table 4). All four variants were imputed
(with r2 > 0.5) and had MAF higher than 5%. At 2p14,
rs12470785 (r2= 0.98) is within an intron of ETAA1. At
13q13.1, rs79183898 (r2= 0.84) is located between B3GALTL
and RXFP2 and rs736596 (r2= 0.66) is within an intron of
STARD13. At 13q13.2, rs4943263 (r2= 0.99) is located between
RP11-266E6.3 and RP11-307O13.1. None of these SNPs had been
previously reported to be associated with BC risk in BCAC studies
in the general population (p-values from 0.01 to 0.90 in BCAC
case-control analyses)35,48. The OR estimates of these four SNPs
ranged from 0.85 to 1.37. All showed evidence of heterogeneity in
the OR by country at p= 0.05 (Table 4). In the leave-one-
country-out sensitivity analysis the two intergenic SNPs,
rs79183898 and rs736596 were no longer significant at P < 10−4
when studies from the USA were excluded from the analysis and
the OR estimates were substantially attenuated (Supplementary
Figs. 3 and 4).
In silico analyses on credible causal variants (CCV). In order to
determine the likely target genes of each region of the eight novel
mutation carriers’ BC risk-associated SNPs, we first defined
credible set of SNPs candidates to be causal (credible causal
variants [CCVs]) (see “Methods”).
Sets of CCVs were sought for the two regions found in the
previous step-wise analyses to be associated with risk in BRCA1
mutation carriers. In the region located at 11p11.2, only one
signal composed of 74 CCVs was found (Table 5). All these 74
CCVs were imputed with a r2 higher than 0.92 (Supplementary
Data 6). In the region located in 17q21.2, we found nine signals
which contained from one to 13 CCVs (Table 5). Two of these
CCVs were genotyped and the others had an r2 between 0.50 and
0.98 (Supplementary Data 6).
We used INQUISIT35,54 to prioritize target genes by intersect-
ing each CCV with publicly available annotation data from breast
cells and tissues (see “Methods”). The results for BRCA1mutation
carriers are summarized in Supplementary Data 7. For BRCA1
mutation carriers, we predicted 38 unique target genes for six of
the 10 independent signals. Seven target genes in two regions
(MTCH2, MADD, PSMC3, RP11-750H9.5, SLC39A13, SPI1, and
EIF1) were predicted with high confidence (designated Level 1,
scoring range between Level 1 [highest confidence] to Level 3
[lowest confidence]). All seven Level 1 genes were predicted to be
distally regulated by CCVs.
Similarly, sets of CCVs were sought from the four regions
found in the previous step-wise analyses to be associated with risk
in BRCA2 mutation carriers. A total of 17 signals were found.
One signal composed of 78 CCVs was found in the region located
at 2p14 (Table 6). One CCV was genotyped and the others were
imputed with r2 between 0.95 and 0.99 (Supplementary Data 8).
Twelve signals were found from the two regions previously found
in 13q13.1 which contained from one to 46 CCVs. The analysis in
the region of rs79183898 in 13q13.1 found three signals out of the
12, which are located in 13q12.3 (with top SNPs: rs71434801,
rs77197167, rs114300732). Finally, four signals in the previously
identified region located in 13q13.2 containing from three to 40
CCVs were found. Among all CCVs, 11 are genotyped and the
imputed ones have an r2 higher than 0.58 (Table 6 and
Supplementary Data 8).
For BRCA2 mutation carriers, we predicted 24 unique target
genes for 10 of the 17 independent signals, including one high
confidence target gene, STARD13 at chr13:33395975-34395975.
STARD13 was also predicted to be targeted by three independent
signals. All results are presented in Supplementary Data 9.
Discussion
To identify novel genetic modifiers of BC risk for BRCA1 and
BRCA2 mutation carriers and to further clarify the effects of
known BC susceptibility SNPs on BC risk for carriers, a novel
case-only analysis strategy was used based on GWAS data from
unselected BC cases in BCAC and mutation carriers with BC
from CIMBA. This strategy provides increased statistical power
for detecting new associations and for clarifying the risk asso-
ciations of known BC susceptibility SNPs in mutation carriers55.
Of the 179 known BC susceptibility SNPs identified through
GWAS in the general population5–35, only 10 showed evidence of
interaction with BRCA1 or BRCA2 mutation carrier status after
taking the tumour ER-status into account. None of these 10 SNPs
was among the fifty SNPs previously shown to be associated with
BC for mutation carriers5,6,15,18,20,39–48. However, 82% of all 179
known susceptibility SNPs showed a predicted OR point estimate
for mutation carriers closer to 1 than that estimated in the general
population. The effect sizes in the general population may be
Table 2 Known BC susceptibility SNPs demonstrating associations in the BRCA2 case-only analysis.
Location SNP namea Chrb Positionc Nearest gene Estimated
effect allele
Referent allele Frequencyd r2 ORe Pf ORBCACg PBCACh ORcomputedi Variation
in riskj
5q11.2 rs62355902 5 56053723 MAP3K1 T A 0.18 0.98 0.89 1.10e−04 1.18 8.50e−42 1.05 TT1
9q31.2 rs10759243 9 110306115 RP11-438P9.2 A C 0.31 1 0.89 4.60e−06 1.06 4.20e−10 0.95 TT1
22q13.1 chr22_40876234_C_T 22 40876234 MKL1 C T 0.11 1 0.88 2.8e−04 1.12 5.70e−16 0.98 TT1
N= 62,822 breast cancer cases (57,725 BCAC cases and 5,097 BRCA2 mutation carrier cases).
Considering SNPs with known BC (Michailidou et al.)35 associations in the general population.
TT1 tends to 1, ISD increase in same direction, IOD increase in opposite direction.
aAfter allowing for multiple testing, α*= 2.7 × 10−4.
bChromosome.
cBuild 37 position.
dFrequency of the allele for which effect is estimated in BCAC cases (OncoArray dataset).
ePer allele odds ratio estimated in the case-only analysis. OR values were computed from a two sided logistic regression using a 1 df lrtest adjusted for age at BC diagnosis, country and the first four
principal components.
fp-value in the case-only analysis (after allowing for multiple testing, p*= 2.7 × 10−4).
gPer allele odds-ratio estimated in BCAC (Michailidou et al.)35.
hp-value in BCAC (Michailidou et al.)35. For SNPs with PBCAC > 10−8, significance was attained in merging data of Oncoarray, iCOGS and 11 different breast cancer GWAS in Michailidou et al.35.
iPer allele computed odds-ratio (OR × ORBCAC).
jCompared with Michailidou et al’s OR estimates35.
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somewhat exaggerated as the BCAC dataset used here contributed
to the discovery of most of the loci, although this effect is likely to
be small as most loci are highly significant and the effects have
been replicated in independent datasets7. Taken together, these
results suggest that, while most SNPs associated with risk in the
general population are associated with risk for mutation carriers,
the average effect sizes for mutation carriers are smaller. These
findings are in line with previous results by Kuchenbaecker
et al.49 and suggest that a PRS built using data from the general
population will have a smaller effect size for BRCA1/2 mutation
carriers.
For 10 SNPs, an interaction was observed with BRCA1 or
BRCA2 mutation carrier status, suggesting that these SNPs have
different effect sizes in BRCA1 or BRCA2 mutation carriers
compared to the general population (seven for BRCA1 mutation
carriers and three for BRCA2 mutation carriers). Specifically, for
seven SNPs the confidence intervals were consistent with no effect
on BC risk for mutation carriers, one SNP was associated with a
larger OR for mutation carriers compared to the general popu-
lation and two were associated in the opposite direction to that
observed in the general population. However, distinguishing
between a smaller effect size for mutation carriers compared to
the general population OR estimates and no association for
mutation carriers is very challenging since, even with the large
sample size here, it is not possible to estimate precisely the effect
sizes for individual variants. Larger sample sizes will be required
for this purpose. Determining the precise effects of the SNPs in
BRCA1 and BRCA2 mutation carriers will provide insights for
understanding the biological basis of cancer development asso-
ciated with BRCA1 and BRCA2 mutations.
We also identified eight novel conditionally independent
common SNPs associated with BC risk (four for BRCA1 mutation
carriers, four for BRCA2 mutation carriers). These have not been
reported in previous association studies5,6,15,18,20,39–47. The case-
only OR estimates for these SNPs varied from 0.85 to 1.37 for
BRCA2 mutation carriers and from 0.78 to 1.22 for BRCA1
mutation carriers. For five of these SNPs the estimated ORs from
the case-only analysis results were in the same direction as the
estimated HRs from previously reported GWAS using cohort
analyses restricted in BRCA1 and BRCA2 mutation carriers in
CIMBA56. Two of these five SNPs also demonstrated some evi-
dence of association in mutation carriers (p= 2.2 × 10−2 for
rs58117746 for BRCA1 mutation carriers; and p= 7.7 × 10−5 for
rs12470785 in ETAA1 for BRCA2 mutation carriers; Tables 3 and
4). For the remaining three variants, rs5820435 and rs11079012 at
17q21.2 and rs736596 at 13q13.1, the associations in BRCA1 or
BRCA2 mutation carriers in the CIMBA data were not consistent
with the observed interactions and might be artefactual. One
possibility is that the associations with SNPs on 17q and 13q in
BRCA1 and BRCA2 carriers respectively, reflect confounding due
to linkage disequilibrium (LD) with specific mutations. Although
we excluded variants with evidence of association in the control
only analyses, it is possible that residual confounding due to
specific mutations was still present.
Seven genes at a locus at 11p11.2 marked by rs60882887, were
predicted with high confidence as targets, including MADD, SP11
and EIF1 which have previously been reported to be associated
with BC biology57–59. However, no likely target genes were pre-
dicted at the 17q21.2 region. The lack of target gene predictions
may be due to reliance on breast cell line data which does not
represent the in vivo tissue of interest or due to the fact that the
target transcripts are not annotated.
Only one gene, STARD13, was predicted as a potential target of
SNPs at 13q13.1. This tumour suppressor gene has been pre-
viously implicated in metastasis, cell proliferation and develop-
ment of BC60. However, rs736596, localized at 13q13.1, showed
no association in CIMBA analyses and the association observed
in our case-only analysis showed heterogeneity by country.
At the 2p14 locus, INQUISIT-predicted target genes included
ETAA1 with lower confidence. The OR estimates obtained in the
case-only analysis for the SNPs located in this gene were con-
sistent with the HR estimated in previously reported CIMBA
analyses56. Moreover, around one hundred correlated SNPs, were
associated with BRCA2 mutation carrier status at p < 10−8,
including the genotyped SNP chr2_67654113_C_T.
The validity of the case-only analysis as evidence of interaction
relies on the assumption of independence between the mutation
status and the SNPs under investigation61. Therefore, based on
the control-only analyses, we excluded ~2,000 SNPs which were
associated with BRCA1 or BRCA2 mutation carrier status and
also showed an association with risk in the case-only analyses
(Supplementary Fig. 5). While most of these associations are
probably spurious, due to (intra- or inter-chromosomal) LD with
BRCA1 or BRCA2 mutations, it is possible that some may reflect
true associations and that the higher frequency in unaffected
BRCA1/2 may be because they are relatives of BC cases. These
associations may warrant further evaluation using other study
designs. A recent publication using data from the Framingham
Heart Study suggested that interchromosomal LD can be caused
by bio-genetic mechanisms possibly associated with favourable or
unfavourable epistatic evolution62. SNPs for which no association
with mutation carrier status was found at the significance level of
10−8 were assumed to be independent of the mutation status.
However, this does not necessarily rule out residual LD between
the novel SNPs on chromosomes 13 and 17 and BRCA1 or
BRCA2 mutations. Therefore, the OR estimates for these SNPs
might be biased and may further explain the lack of evidence of
association in the CIMBA only analyses.
Our findings highlight the importance of imputation in GWAS.
The imputed genome-wide genotype data used in the main case-
only association analyses were based on carrying out the impu-
tation separately for the BC cases from BCAC and CIMBA. We
found that 28 out of the 33 regions associated with BRCA1 or
BRCA2 mutation carrier status were no longer associated with
risk after re-imputing all samples together. By re-imputing all the
data together we ensured that the associations observed for the
remaining regions are robust to potential differences in the
imputation accuracy between the BCAC and CIMBA samples.
Under our analytical strategy, only the regions for which evi-
dence of associated with BC risk was observed were re-imputed
using all BCAC and CIMBA samples combined. This re-
imputation was not done at genome-wide level due to compu-
tational constraints and this may have led to false-negative
associations being excluded for further evaluation as potential
novel modifiers. Future analyses should aim to analyse the
genome-wide associations after the genome-wide re-imputation
across the combined BCAC and CIMBA dataset. However, our
approach using joint one-step imputation should have ensured
that associations we report (all of which are common SNPs with
imputation scores > 0.5) are not driven by inaccuracies in
imputation.
Due to the recruitment of participants in CIMBA studies pri-
marily through genetic counselling, the mean age at diagnosis of
mutation carriers was 16 years younger than the BC cases par-
ticipating in BCAC. Although all analyses were adjusted for age,
the observed associations might be related to the ageing process
instead of interactions with mutation carrier status. Another
source of bias could be related to the fact that there are 1.5 times
more prevalent cases among CIMBA (68.1%) than BCAC (42.3%)
with a delay between diagnosis and study recruitment of 6.83
years and 2.07 years respectively. An observed association might
be due to a differential survival between CIMBA and BCAC cases.
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However, none of the identified SNPs has been found to be
associated with BC survival63.
The majority (92.5%) of cases and controls in BCAC were not
tested for BRCA1/2 mutations at the time of enrolment, poten-
tially leading to some attenuation in the interaction OR (as some
BCAC cases will be carriers). However, most BCAC studies were
population-based case-control studies and the proportion of cases
and controls that carry pathogenic BRCA1/2 mutations will be
small (<5%), hence any attenuation is likely to be negligible.
Despite heterogeneity in the interaction ORs by country for
some SNPs, results were generally robust to the exclusion of each
country sequentially except, for two SNPs (rs79183898 and
rs736596) found associated with BRCA2 mutation carrier status;
for these, the association seemed to be driven by data from the
USA. For the other SNPs, the observed heterogeneity may be due
to random error, given the relatively small sample sizes of each
country. However, if these differences are real, future PRS for
BRCA1 and BRCA2 carriers should consider the country-specific
differences.
This is the first analysis of genetic modifiers of BC risk that
investigated the differences in the association of common genetic
variants with BC risk in the general population and in women
with BRCA1 or BRCA2 mutations. The inclusion of unselected
BC cases resulted in increased sample size and hence a gain in
statistical power for identifying novel SNPs. These represent the
largest currently available datasets, but it is important to replicate
these observations in independent samples. This should be pos-
sible through the ongoing CONFLUENCE (https://dceg.cancer.
gov/research/cancer-types/breast-cancer/confluence-project)
large-scale genotyping experiment. More detailed fine mapping
and functional analysis will be required to elucidate the role of the
novel variants identified in BC development for BRCA1 and
BRCA2 mutation carriers. Our findings should contribute to the
improved performance of BC PRS for absolute risk prediction for
BRCA1 and BRCA2 mutation carriers, which will help inform
decisions on the best timing for risk-reducing surgery, risk
reduction medication, or the start of surveillance.
Methods
Study sample. We used data from two international consortia, BCAC64 and
CIMBA56. BCAC included data from 108 studies of BC from 33 countries in North
America, Europe and Australia, the majority (88%) of which were case-control
studies. The majority of BCAC cases/controls were not tested for BRCA1/2
mutations at the time of enrolment. However, most studies were population-based,
hence the proportion of cases and controls that carry pathogenic BRCA1/2
mutations will be small. CIMBA participants were women with pathogenic
mutations in BRCA1 or BRCA2. All participants were at least 18 years old. The
majority of mutation carriers were recruited through cancer genetics clinics and
enroled into national or regional studies. Data were available on 30,500 BRCA1
mutation carriers and 20,500 BRCA2 mutation carriers from 77 studies in 32
countries. A total of 188,320 BC cases and 161,669 controls were available from
both consortia. All studies provided information on disease status, age at diagnosis
or at interview. Oestrogen receptor status was available for 72% of BCAC cases and
71% of CIMBA cases. All subjects provided written informed consent and parti-
cipated in studies with protocols approved by ethics committees at each partici-
pating institution.
Sample selection. BCAC cases were women diagnosed with BC7. To define disease
status in CIMBA participants, women were censored at the first of the following
events: age at BC diagnosis, age at ovarian cancer diagnosis, other cancer, bilateral
prophylactic mastectomy or age at study recruitment. Subjects censored at a BC
diagnosis were considered as cases.
A control-only analysis was carried out to test the independence between the
SNPs and the BRCA1 and BRCA2 mutation carrier status. In BCAC, controls were
defined as individuals unaffected by BC at study recruitment35. In CIMBA,
participants were considered as controls if they were unaffected at recruitment.
Only women of European ancestry were included. To minimise the chance of
observing spurious associations due to differences in the distribution of BC cases in
the population by tumour characteristics (defined as unselected BC cases), 3,478
BCAC cases from four studies were excluded because they were included in clinical
trials based on breast tumour characteristics as HER-2 receptor status (see
Supplementary Table 2). Because all the analyses were adjusted for country, to
ensure that the number of subjects in each country stratum was large enough, we
excluded the CIMBA data from any country for which there were less than ten BC
cases with BRCA1 or BRCA2 mutation. Consequently, data from Poland and
Russia were excluded from the BRCA2 analyses (Supplementary Table 3). Finally,
duplicate subjects between BCAC and CIMBA were excluded from the BCAC data
(114 and 80 subjects from the BRCA1 and BRCA2 case-only analyses, respectively;
eight subjects from control-only analyses).
A total of 60,212 BCAC cases and 7,257 BRCA1 mutation carrier cases were
available for the BRCA1 case-only analyses and 57,725 BCAC cases and 5097
BRCA2 mutation carrier cases were available for the BRCA2 case-only analyses
(Fig. 1). A total of 45,881 BCAC controls and 5,750 BRCA1 mutation carrier
controls were available for the BRCA1 control-only analyses and 43,549 BCAC
controls and 4,456 BRCA2 mutation carrier controls for the BRCA2 control-only
analyses (Fig. 2).
Genotype data. All the study samples were genotyped using the OncoArray
Illumina beadchip65. The array includes a backbone of ~260,000 SNPs that provide
genome-wide coverage of most common variants, together with markers of interest
for breast and other cancers identified through GWAS, fine-mapping of known
susceptibility regions, and other approaches65.
A standard genotype quality control process was followed for both the BCAC
and CIMBA samples which have been described in detail elsewhere35,48. Briefly,
this involved excluding SNPs located on chromosome Y; SNPs with call rates
<95%; SNPs with MAF < 0.05 and call rate <98%; monomorphic SNPs; and SNPs
for which evidence of departure from Hardy-Weinberg equilibrium was observed
(P < 10−7 based on a country-stratified test).
Genotypes for ~21 million SNPs were imputed for all subjects using the 1000
Genomes Phase III data (released October 2014) as reference panel, as described
previously66. Briefly, the number of reference haplotypes used as templates when
imputing missing genotypes was fixed to 800 (-k_hap= 800). A two-stage
imputation approach was used: phasing with SHAPEIT67,68 and imputation with
IMPUTE269 using 5 Mb non-overlapping intervals. Genotypes were imputed for all
SNPs that were found polymorphic (MAF > 0.1%) in either European or Asian
populations.
The genome-wide imputation process described above was carried out
separately for the BCAC and CIMBA samples. However, this may potentially lead
to spurious associations if there are differences in the quality of the imputation
(measured using the imputation accuracy r² metric70) for a given SNP between the
two datasets. To address this, a stringent approach was employed which involved
including only SNPs for which the difference in r² between the BCAC and CIMBA
SNP imputations (Δr²) was minimal relative to their r² values. SNPs with r² > 0.9 in
both BCAC and CIMBA were kept in the analyses only if Δr² < 0.05; SNPs with 0.8
< r² ≤ 0.9 in both BCAC and CIMBA were kept if Δr² < 0.02 and, SNPs with 0.5 <
r² ≤ 0.8 in both BCAC and CIMBA were kept if Δr² < 0.01. All SNPs with r² < 0.5 in
either CIMBA or BCAC were excluded. Only SNPs with a MAF > 0.01 in BCAC
cases were included.
Consequently, 9,072,535 SNPs were included in the BRCA1 analyses (402,336
genotyped and 8,670,199 imputed SNPs) and 9,047,403 SNPs in the BRCA2
analyses (402,397 genotyped and 8,645,006 imputed SNPs).
Case-only and control-only analyses. The comparison of SNP frequency between
CIMBA cases and BCAC cases (case-only analyses), or between unaffected CIMBA
subjects and BCAC controls (control-only analyses), was performed using logistic
regression adjusted for age at BC diagnosis in the case-only analyses and for age at
interview for BCAC controls or at censure for CIMBA unaffected subjects in the
control-only analyses, as well as for country and principal components (PCs) to
account for population structure. Separate analyses were carried out for BRCA1
and BRCA2 mutation carriers. To define the number of PC for inclusion in the
models, the principal component analysis was carried out using 35,858 uncorre-
lated genotyped SNPs on the OncoArray and purpose-written software (http://
ccge.medschl.cam.ac.uk/software/pccalc/). The inflation statistic was calculated and
converted to an equivalent statistic for a study of 1,000 subjects for each outcome
(λ1,000) by adjusting for effective study size:







where n and m are the numbers of BCAC and CIMBA subjects respectively. The
models were adjusted with the first four PCs (λ1,000 with and without PCs in the
model= 1.03 and 1.21, respectively) since additional PCs did not result in further
reduction in the inflation of the test statistics.
Strategy for determining significant associations. The analytical process is
summarised in Figs. 3 and 4. A fundamental assumption when using a case-only
design in this context is that the SNPs and mutation carrier status are independent61.
To confirm independence, SNPs likely to be in linkage disequilibrium (LD) with
BRCA1 or BRCA2 mutations, i.e., those located in or within 500 kb of either gene,
were excluded. However, LD also exists between variants at long-distance on the
same chromosome or even on a different chromosome (interchromosomal LD)62,71.
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Therefore, control-only analyses were performed to further exclude SNPs associated
with mutation carrier status in unaffected women72, using a stringent statistical
significance level of 10−8).
After excluding SNPs in LD or in interchromosomal LD with BRCA1 or BRCA2
mutations, case-only analyses were performed to assess the association between
SNPs and BRCA1 or BRCA2 mutation carrier status. We considered two categories
of SNPs depending on whether they had been previously found to be associated
with BC in published BCAC studies35,48. For known BC susceptibility SNPs (Fig. 3)
we used a significance threshold of 2.7 × 10−4 (applying Bonferroni correction to
179 tests) and for potential novel SNP modifier (Fig. 4) a stringent significance
threshold of 10−8 was used.
Because BRCA1mutation-associated tumours are more often ER-negative than
those in the general population73, a subsequent case-only analysis was performed
restricting the BCAC cases to those with ER-negative disease. We used this strategy
for two reasons. First, we wished to exclude associations driven by differences in
the tumour ER-status distributions between BRCA1 carriers and BCAC cases.
Therefore, in the BRCA1 analysis, SNPs were considered to be associated with
mutation carrier status only if they were also associated in the ER-negative case-
only analysis at a prior defined significance threshold of 10−7 for novel SNP
modifiers (Fig. 4) and of 0.05 for the established BC susceptibility SNPs after a pre-
selection at P < 2.7 × 10−4 in the BRCA1 overall case-only analysis (Fig. 3). The
second reason we applied this strategy was to identify novel SNP modifiers specific
to BRCA1/ER-negative tumours that had not been detected in the overall analysis;
for this we applied a significance threshold of 10−8.
To confirm that potentially novel associations in the case-only analysis were not
driven by differences in the imputation accuracy between the CIMBA and BCAC
data, each of the regions defined as ±500 kb around the associated SNP, were re-
imputed for the combined CIMBA and BCAC samples. The more accurate one-stage
imputation was carried out, using IMPUTE2 without pre-phasing. Associations with
all the SNPs in the re-imputed regions were then re-evaluated using the control-only
and case-only analytical approaches described above. Finally, we used a step-wise
regression analysis using a significance threshold of 10−8 in order to determine
whether associations with SNPs in the same region are independent and to define the
conditionally independent SNPs (top SNPs).
Among the 179 established BC susceptibility SNPs, 107 were genotyped and 71
were imputed. As previously, although none of these 71 SNPs were excluded based on
their Δr², to exclude potentially spurious associations, regions around these 71 SNPs
were re-imputed using the one-stage imputation applied to BCAC and CIMBA data
combined, and before performing the control-only and case-only analyses.
Determining the magnitude of association. For the potentially novel SNP
modifiers the risk ratio of BC applicable to mutation carriers was assumed to be
equal to the OR estimate from the case-only analysis (with the hypothesis that their
relative risk equals 1 in the general population, given that none of them was found
to be associated with BC in BCAC)55.
For the known BC susceptibility SNPs, a significant association in the case-only
analysis implies that the magnitude of association is different for BRCA1 or BRCA2
mutation carriers than for the general population. Therefore, the risk ratio of BC
for mutation carriers was computed as the product of OR × ORBCAC where OR was
obtained from the case-only analysis, and ORBCAC was the odds ratio of association
obtained from either Michailidou et al.35 for the SNPs associated with overall BC
risk and from Milne et al.48 for the SNPs associated with ER-negative BC.
For all associated SNPs in case-only analyses, heterogeneity by country was
assessed using likelihood ratio tests that compared models with and without an
SNP by country interaction term. When the heterogeneity test was significant at P
< 0.05, a leave-one-out analysis was performed, by excluding each country in turn
to assess the influence of a data from a specific country on the overall association.
Credible causal variants. For each novel region, we defined sets of credible causal
variants (CCVs) to use in the prediction of the likely target genes. For this purpose, we
defined a first set of CCVs including the top SNP of the region of interest and the
SNPs with p-values of association within two orders of magnitude of the top SNP
association. Then, we sequentially performed logistic regression analyses using all
other SNPs in the region, adjusted for the top SNP. We defined a second set of CCVs
which included the most significant SNP after adjusting for the top SNP and the SNPs
with p-values within two orders of magnitude of the most significant SNP association.
This was repeated (conditioning on the previously found most significant SNPs) to
define additional sets of CCVs as long as at least one p-value remained <10−6.
eQTL analysis. Data from BC tumours and adjacent normal breast tissue were
accessed from The Cancer Genome Atlas74 (TCGA). Germline SNP genotypes
(Affymetrix 6.0 arrays) from individuals of European ancestry were processed and
imputed to the 1000 Genomes reference panel (October 2014)35. Tumour tissue
copy number was estimated from the Affymetrix 6.0 and called using the GISTIC2
algorithm75. Complete genotype, RNA-seq and copy number data were available
for 679 genetically European patients (78 with adjacent normal tissue). Further,
RNA-seq for normal breast tissue and imputed germline genotype data were
available from 80 females from the GTEx Consortium76. Genes with a median
expression level of 0 RPKM across samples were removed, and RPKM values of
each gene were log2 transformed. Expression values of samples were quantile
normalized. Genetic variants were evaluated for association with the expression of
genes located within ±2Mb of the lead variant at each risk region using linear
regression models, adjusting for ESR1 expression. Tumour tissue was also adjusted
for copy number variation77. eQTL analyses were performed using the Matrix-
EQTL program in R78.
INQUISIT analyses. Candidate target genes were evaluated by assessing each
CCV’s potential impact on regulatory or coding features using a computational
pipeline, INtegrated expression QUantitative trait and In SIlico prediction of
GWAS Targets (INQUISIT)35,54. Briefly, genes were considered as potential targets
of candidate causal variants through effects on: (1) distal gene regulation, (2)
proximal regulation, or (3) a gene’s coding sequence. We intersected CCV posi-
tions with multiple sources of genomic information chromatin interaction analysis
by paired-end tag sequencing (ChIA-PET79) in MCF7 cells and genome-wide
chromosome conformation capture (Hi-C) in HMECs. We used breast cell line
computational enhancer–promoter correlations (PreSTIGE80, IM-PET81, FAN-
TOM582) breast cell super-enhancer83, breast tissue-specific expression variants
(eQTL) from multiple independent studies (TCGA (normal breast and breast
tumour) and GTEx breast—see eQTL methods), transcription factor and histone
modification chromatin immunoprecipitation followed by sequencing (ChIP-seq)
from the ENCODE and Roadmap Epigenomics Projects together with the genomic
features found to be significantly enriched for all known breast cancer CCVs54,
gene expression RNA-seq from several breast cancer lines and normal samples
(ENCODE) and topologically associated domain (TAD) boundaries from T47D
cells (ENCODE84). To assess the impact of intragenic variants, we evaluated their
potential to alter primary protein coding sequence and splicing using Ensembl
Variant Effect Predictor85 using MaxEntScan and dbscSNV modules for splicing
alterations based on ada and rf scores. Nonsense and missense changes were
assessed with the REVEL ensemble algorithm, with CCVs displaying REVEL scores
>0.5 deemed deleterious.
Each target gene prediction category (distal, promoter or coding) was scored
according to different criteria. Genes predicted to be distally regulated targets of CCVs
were awarded points based on physical links (for example ChIA-PET), computational
prediction methods, or eQTL associations. All CCVs were considered as potentially
involved in distal regulation. Intersection of a putative distal enhancer with genomic
features found to be significantly enriched54 were further upweighted. Multiple
independent interactions were awarded an additional point. CCVs in gene proximal
regulatory regions were intersected with histone ChIP-Seq peaks characteristic of
promoters and assigned to the overlapping transcription start sites (defined as−1.0 kb
– +0.1 kb). Further points were awarded to such genes if there was evidence for eQTL
association, while a lack of expression resulted in down-weighting as potential targets.
Potential coding changes including missense, nonsense and predicted splicing
alterations resulted in addition of one point to the encoded gene for each type of
change, while lack of expression reduced the score. We added an additional point for
predicted target genes that were also breast cancer drivers (278 genes35,54). For each
category, scores potentially ranged from 0 to 8 (distal); 0 to 4 (promoter) or 0 to 3
(coding). We converted these scores into ‘confidence levels’: Level 1 (highest
confidence) when distal score > 4, promoter score ≥3 or coding score >1; Level 2 when
distal score ≤ 4 and ≥1, promoter score= 1 or= 2, coding score= 1; and Level 3
when distal score <1 and >0, promoter score <1 and >0, and coding <1 and >0. For
genes with multiple scores (for example, predicted as targets from multiple
independent risk signals or predicted to be impacted in several categories), we
recorded the highest score.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Among BCAC data used in this study, data from 2SISTER, BREOGAN, CGPS, CPSII,
EPIC, MEC, NBHS, MCCS, NHS, NHS2, PBCS, PLCO, SEARCH, SISTER, SMC,
WAABCS and WHI are available in the dbGaP database under accession code
phs001265.v1.p1. Among CIMBA data used in this study, data from KCONFAB, KUMC,
MAYO, MSKCC, MUV, NCI, NNPIO, NORTHSHORE, OSU CCG, PBCS, SMC, SWE-
BRCA, UCHICAGO, UCSF, UPENN, UPITT, UTMDACC, VFCTG and WCP studies
are available in the dbGaP database under accession code phs001321.v1.p1. The complete
dataset is not publicly available due to restraints imposed by the ethical committees of
individual studies. Requests for the complete data can be made to the corresponding
author or the Data Access Coordinating Committees (DACCs) of BCAC
(BCAC@medschl.cam.ac.uk) and CIMBA (ljm26@medschl.cam.ac.uk). BCAC DACC
approval is required to access data from the following studies ABCFS, ABCS, ABCTB,
BBCC, BBCS, BCEES, BCFR-NY, BCFR-PA, BCFR-UTAH, BCINIS, BSUCH, CBCS,
CECILE, CGPS, CTS, DIETCOMPLYF, ESTHER, GC-HBOC, GENICA, GEPARSIXTO,
GESBC, HABCS, HCSC, HEBCS, HUBCS, KARBAC, KBCP, LMBC, MARIE, MBCSG,
MCBCS, MISS, MMHS, MSKCC, MTLGEBCS, NC-BCFR, OFBCR, ORIGO, PBCS,
pKARMA, POSH, PREFACE, RBCS, SKKDKFZS, SUCCESSB, SUCCESSC, SZBCS,
TNBCC, UCIBCS, UKBGS and UKOPS (see Supplementary Table 2—for a list of all
studies). CIMBA DACC approval is required to access data from studies BCFR-ON,
BRICOH, CONSIT TEAM, DKFZ, EMBRACE, FPGMX, G-FAST, GC-HBOC, GEMO,
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HEBCS, HEBON, IHCC, INHERIT, IOVHBOCS, MCGILL, NRG_ONCOLOGY, OUH
and UKGRFOCR (see Supplementary Table 1—for a list of all CIMBA studies). Case-
control summary results from CIMBA and BCAC consortia are publicly available and
can be downloaded at http://cimba.ccge.medschl.cam.ac.uk/oncoarray-complete-
summary-results/ and at http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/
oncoarray-and-combined-summary-result/gwas-summary-associations-breast-cancer-
risk-2020/). The top 10 000 SNPs from the current BCAC-CIMBA case-only study can
be found at http://cimba.ccge.medschl.cam.ac.uk/projects/BCAC-CIMBA_Case-
only_analysis. The remaining data are available within the Article, Supplementary
Information or available from the authors upon request. Source data are provided with
this paper.
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